Premium
Malignant lymphoma after diphenylhydantoin (dilantin) therapy
Author(s) -
Li Frederick P.,
Willard Douglas R.,
Goodman Robert,
Vawter Gordon
Publication year - 1975
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197510)36:4<1359::aid-cncr2820360426>3.0.co;2-l
Subject(s) - medicine , lymphoma , pathogenesis , malignant lymphoma , disease , phenytoin , oncology , drug , pharmacology , epilepsy , psychiatry
A history of prolonged diphenylhydantoin (Dilantin) therapy was reported by 8 of 516 patients (1.6%) with Hodgkin's disease or non‐Hodgkin's lymphoma, as compared with 3 of 516 patients (0.6%) with other cancers, and 2 of 516 (0.4%) tumor‐free individuals. The findings, together with other published data, suggest a small excess risk of malignant lymphomas in patients receiving long‐term treatment with this drug. The immunosuppressive effects of chronic diphenylhydantoin therapy may be involved in the pathogenesis of these neoplasms.